Tailored Approaches Grounded on Immunogenetic Features for Refined Prognostication in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides abnormalities, del(11q) and/or mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.

Citing Articles

Increased abundance of and depletion of predicts poor outcome in chronic lymphocytic leukemia.

Paziewska M, Szelest M, Kielbus M, Masternak M, Zaleska J, Wawrzyniak E Oncol Lett. 2024; 28(5):552.

PMID: 39328278 PMC: 11425030. DOI: 10.3892/ol.2024.14685.

Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.

Fontecha M, Del Rosario Anadon M, Mercado Guzman V, Stanganelli C, Galvano C, Tosin F Ann Hematol. 2024; 103(12):5703-5712.

PMID: 38743086 DOI: 10.1007/s00277-024-05794-w.

A personalized stepwise dynamic predictive algorithm of the time to first treatment in chronic lymphocytic leukemia.

Moysiadis T, Koparanis D, Liapis K, Ganopoulou M, Vrachiolias G, Katakis I iScience. 2023; 26(9):107591.

PMID: 37664638 PMC: 10470317. DOI: 10.1016/j.isci.2023.107591.

Precision diagnostics in chronic lymphocytic leukemia: Past, present and future.

Mollstedt J, Mansouri L, Rosenquist R Front Oncol. 2023; 13:1146486.

PMID: 37035166 PMC: 10080996. DOI: 10.3389/fonc.2023.1146486.

Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles.

Deng X, Zhang M, Wang J, Zhou X, Xiao M Front Oncol. 2023; 13:1120867.

PMID: 36874132 PMC: 9978106. DOI: 10.3389/fonc.2023.1120867.

References

Ntoufa S, Vardi A, Papakonstantinou N, Anagnostopoulos A, Aleporou-Marinou V, Belessi C . Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med. 2012; 18:1281-91. PMC: 3521790. DOI: 10.2119/molmed.2011.00480. View

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

Kulis M, Heath S, Bibikova M, Queiros A, Navarro A, Clot G . Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012; 44(11):1236-42. DOI: 10.1038/ng.2443. View

Stevenson F, Caligaris-Cappio F . Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004; 103(12):4389-95. DOI: 10.1182/blood-2003-12-4312. View

Hallek M . Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015; 90(5):446-60. DOI: 10.1002/ajh.23979. View

Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F . Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2017; 32(3):675-684. PMC: 5843901. DOI: 10.1038/leu.2017.251. View

Landau D, Tausch E, Taylor-Weiner A, Stewart C, Reiter J, Bahlo J . Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-30. PMC: 4815041. DOI: 10.1038/nature15395. View

Marincevic M, Cahill N, Gunnarsson R, Isaksson A, Mansouri M, Goransson H . High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica. 2010; 95(9):1519-25. PMC: 2930953. DOI: 10.3324/haematol.2009.021014. View

10.

Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton L, Minga E, Tsanousa A . Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015; 125(5):856-9. PMC: 4311230. DOI: 10.1182/blood-2014-09-600874. View

11.

Cramer P, Hallek M . Prognostic factors in chronic lymphocytic leukemia-what do we need to know?. Nat Rev Clin Oncol. 2010; 8(1):38-47. DOI: 10.1038/nrclinonc.2010.167. View

12.

Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton L . No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica. 2017; 103(4):e158-e161. PMC: 5865420. DOI: 10.3324/haematol.2017.182634. View

13.

Gentile M, Mauro F, Rossi D, Vincelli I, Tripepi G, Recchia A . Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol. 2014; 167(2):224-32. DOI: 10.1111/bjh.13032. View

14.

Baliakas P, Hadzidimitriou A, Agathangelidis A, Rossi D, Sutton L, Kminkova J . Prognostic relevance of MYD88 mutations in CLL: the jury is still out. Blood. 2015; 126(8):1043-4. PMC: 4598193. DOI: 10.1182/blood-2015-05-648634. View

15.

. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6):779-790. DOI: 10.1016/S1470-2045(16)30029-8. View

16.

Baliakas P, Hadzidimitriou A, Sutton L, Rossi D, Minga E, Villamor N . Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2014; 29(2):329-36. DOI: 10.1038/leu.2014.196. View

17.

Fischer K, Bahlo J, Fink A, Goede V, Herling C, Cramer P . Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2015; 127(2):208-15. DOI: 10.1182/blood-2015-06-651125. View

18.

Thompson P, Tam C, OBrien S, Wierda W, Stingo F, Plunkett W . Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2015; 127(3):303-9. PMC: 4760129. DOI: 10.1182/blood-2015-09-667675. View

19.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton L, Minga E . Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clin Cancer Res. 2017; 23(17):5292-5301. DOI: 10.1158/1078-0432.CCR-16-3100. View

20.

Wierda W, OBrien S, Wang X, Faderl S, Ferrajoli A, Do K . Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007; 109(11):4679-85. DOI: 10.1182/blood-2005-12-051458. View